Abstract 170P
Background
1.4 million new prostate cancer cases were detected in 2020. Survival has improved in metastatic castration-resistant prostate cancer (mCRPC) because of the development of effective drugs such as abiraterone acetate, but universal accessibility to treatment is not always possible because of cost constraints in lower- and middle-income countries. Abiraterone in fasting state is the standard of care in mCRPC. Despite a large food effect, it was administered under fasting conditions in its pivotal trials. Recently, the National Comprehensive Cancer Network (NCCN) has included low-dose abiraterone (250 mg/day) with food as an alternative treatment option to full-dose abiraterone (1,000 mg/day) fasting. This translates to 75% cost reduction.
Methods
In this cohort study mCRPC Patients with progression were offered low dose abiraterone with low fat meal along with prednisone 5 mg twice daily. Prostate-specific antigen (PSA) was assessed monthly and toxicity assessment was made every week. Final PSA response (≥ 50% reduction) and toxicity assessment were done at 12 weeks. In case of grade IV toxicity (Anemia, Hypertension, Hypokalemia, hypocalcemia – CTC AE V5.0) because of higher drug bioavailability, patient would be offered full dose abiraterone. 20 patients were offered low dose abiraterone in 2020.
Results
12 out of 20 (60%) patients achieved desired PSA response at 12 weeks which is a bit on higher side compared to standard dose abiraterone (recent literature). Fortunately, none of the patient developed grade IV toxicity. This finding was assuring, and no patient shifted to standard dosing.
Conclusions
Low dose abiraterone (with low-fat breakfast) is noninferior to full dose abiraterone with respect to PSA metrics. Toxicity is the major thing to look at and given the pharmacoeconomic implications it’s imperative to adopt this strategy in places where affordability is the issue. Let the patients have something rather than nothing!
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
237P - Dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity modulated radiotherapy to ipsilateral neck
Presenter: Manish Chomal
Session: Poster viewing 03
238P - Proposing a predictive nomogram for lymph-node metastasis (LNM) in oral squamous cell carcinoma (OSCC) using immunohistochemical marker D2-40
Presenter: Karen Boaz
Session: Poster viewing 03
239P - Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Presenter: Abhinav Thaduri
Session: Poster viewing 03
240P - SERPINE2 promotes the growth, invasion, and metastasis in oral squamous cell carcinoma and is associated with poor prognosis
Presenter: Hao-Wen Chuang
Session: Poster viewing 03
241P - P16 IHC stain is an useful marker for predicting outcome of oropharyngeal cancer in Taiwan
Presenter: chiencheh chen
Session: Poster viewing 03
242P - Epidemiology and survival analysis of head and neck cancer: Results from a comprehensive care center in North India
Presenter: Amit Badola
Session: Poster viewing 03
243P - Induction bio-chemotherapy or bio-chemoimmunotherapy for locally advanced betel-nut-related HNSCC in Taiwan
Presenter: Jo Pai Chen
Session: Poster viewing 03
244P - Alternate-day hypofractionated radiotherapy for radical treatment of head & neck cancer during the COVID-19 pandemic: A single institute experience
Presenter: Pragya Singh
Session: Poster viewing 03
246P - Clinicoepidemiological profile and patterns of failure in carcinoma oral cavity in Indian patients: A 6-year retrospective study
Presenter: Aashita -
Session: Poster viewing 03